Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06535607 · ClinicalTrials.gov registry record · Phase 2

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

A Phase 2 study of Cervical Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 2
Development phase
110
Enrollment target
20
Study locations

NCT06535607 is a Phase 2 study of Cervical Cancer and Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 110 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06535607, a Phase 2 study of Cervical Cancer and Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 2
Development phase
110 participants
Enrollment target
20
Study locations

Study Summary

eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.

Conditions Studied

Cervical Cancer Head and Neck Squamous Cell Carcinoma

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Paclitaxel
  • BIOLOGICAL Volrustomig

Study Locations (20)

Other

  • Research Site - Ijuí
  • Research Site - Londrina
  • Research Site - São Caetano do Sul
  • Research Site - Vitória
  • Research Site - Beijing
  • Research Site - Beijing
  • Research Site - Beijing
  • Research Site - Bengbu
  • Research Site - Changchun
  • Research Site - Changsha
  • Research Site - Changsha
  • Research Site - Changsha
  • Research Site - Changsha
  • Research Site - Chengdu
  • Research Site - Chengdu
  • Research Site - Chongqing

California

  • Research Site - Los Angeles

Maryland

  • Research Site - Baltimore

New York

  • Research Site - Stony Brook

Ohio

  • Research Site - Columbus

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2024-08-22
Est. Completion 2028-11-30
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06535607

The ClinicalTrials.gov registry entry for NCT06535607 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (81% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.

NCT06535607 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT06535607 about?

NCT06535607 is a clinical study titled "Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors". eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.

What is the current status of trial NCT06535607?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2024-08-22. Estimated completion is 2028-11-30.

What conditions does trial NCT06535607 study?

This clinical trial studies the following conditions: Cervical Cancer, Head and Neck Squamous Cell Carcinoma.

What interventions are being tested in trial NCT06535607?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Paclitaxel (DRUG), Volrustomig (BIOLOGICAL).

Who is sponsoring clinical trial NCT06535607?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06535607 being conducted?

This trial has 20 study locations across California, Maryland, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cervical Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cervical Cancer

All registered trials for this condition

Head and Neck Squamous Cell Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.